|
186 Companies |
|
244 Products |
|
244 Products |
|
91 Mechanisms of Action |
|
17 Trials |
|
2576 News |
|
| «12...4567891011121314...5253» |
- CMD-602 / Cell and Gene Therapy Catapult, Athenex, Baylor College of Medicine
Trial primary completion date, IO biomarker, Gene therapy: WT1 TCR Gene Therapy for Leukaemia: A Phase I/II Safety and Toxicity Study (clinicaltrials.gov) - Jan 11, 2017
P1/2, N=18, Recruiting, Sponsor: Cell Therapy Catapult
Trial primary completion date: Sep 2018 --> May 2019
- Thymoglobulin (anti-thymocyte globulin (rabbit)) / Sanofi
Trial primary completion date: Fludarabine-Based Conditioning for Allogeneic Marrow Transplantation in Aplastic Anemia (clinicaltrials.gov) - Jan 11, 2017
P1/2, N=94, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Trial primary completion date: Sep 2018 --> May 2019 Trial primary completion date: Feb 2018 --> Feb 2019
- ||||| Pegasys (pegylated interferon α -2a) / Roche
Enrollment closed, Enrollment change, Trial primary completion date: Randomized Trial of Pegylated Interferon Alfa-2a Versus Hydroxyurea in Polycythemia Vera (PV) and Essential Thrombocythemia (ET) (clinicaltrials.gov) - Jan 11, 2017
P3, N=168, Active, not recruiting, Sponsor: Ronald Hoffman
Trial primary completion date: Feb 2018 --> Feb 2019 Recruiting --> Active, not recruiting | N=300 --> 168 | Trial primary completion date: Jun 2024 --> Jun 2017
- |||| Pegasys (pegylated interferon α -2a) / Roche
Trial completion, Enrollment change, Trial primary completion date: Pegylated Interferon Alfa-2a Salvage Therapy in High Risk Polycythemia Vera (PV) or Essential Thrombocythemia (ET) (clinicaltrials.gov) - Jan 11, 2017
P2, N=135, Completed, Sponsor: Ronald Hoffman
Recruiting --> Active, not recruiting | N=300 --> 168 | Trial primary completion date: Jun 2024 --> Jun 2017 Recruiting --> Completed | N=188 --> 135 | Trial primary completion date: Jun 2018 --> Dec 2016
- volasertib (NBL-001) / Oncoheroes, Notable Labs
Enrollment change, Trial termination, Combination therapy: Phase I Dose Escalation Trial of Volasertib in Combination With Azacitidine in Patients With MDS or CMML (clinicaltrials.gov) - Jan 11, 2017
P1, N=16, Terminated, Sponsor: Boehringer Ingelheim
Recruiting --> Completed | N=188 --> 135 | Trial primary completion date: Jun 2018 --> Dec 2016 N=88 --> 16 | Suspended --> Terminated
- Trial primary completion date: Improving Blood Stem Cell Collection and Transplant Procedures (clinicaltrials.gov) - Jan 10, 2017
P1/2, N=43, Active, not recruiting, Sponsor: National Heart, Lung, and Blood Institute (NHLBI)
N=88 --> 16 | Suspended --> Terminated Trial primary completion date: Dec 2016 --> Dec 2017
- | Synribo (omacetaxine mepesuccinate) / Teva
Trial completion, Enrollment change, Trial primary completion date: Omacetaxine and Low Dose Cytarabine in Older Patients With Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS) (clinicaltrials.gov) - Jan 9, 2017
P2, N=36, Completed, Sponsor: M.D. Anderson Cancer Center
Trial primary completion date: Dec 2016 --> Dec 2017 Active, not recruiting --> Completed | N=60 --> 36 | Trial primary completion date: Jul 2017 --> Jan 2017
- Clinical: Dual Energy Computed Tomography (CT) in Finding Bone Metastases in Patients With Cancer (clinicaltrials.gov) - Jan 9, 2017
P=N/A, N=45, Recruiting, Sponsor: Case Comprehensive Cancer Center
Active, not recruiting --> Completed | N=60 --> 36 | Trial primary completion date: Jul 2017 --> Jan 2017 Trial primary completion date: Nov 2016 --> Jun 2017
- Enrollment change, Trial primary completion date: Natural History Study of Patients With Chronic Myelogenous Leukemia (clinicaltrials.gov) - Jan 4, 2017
P=N/A, N=48, Completed, Sponsor: Dana-Farber Cancer Institute
Trial primary completion date: Nov 2016 --> Jun 2017 N=2000 --> 48 | Trial primary completion date: Mar 2009 --> Sep 2005
- vorasidenib (S95032) / Servier
Enrollment closed, Trial primary completion date, Metastases: Study of Orally Administered AG-881 in Patients With Advanced Hematologic Malignancies With an IDH1 and/or IDH2 Mutation (clinicaltrials.gov) - Jan 4, 2017
P1, N=46, Active, not recruiting, Sponsor: Agios Pharmaceuticals, Inc.
N=2000 --> 48 | Trial primary completion date: Mar 2009 --> Sep 2005 Recruiting --> Active, not recruiting | Trial primary completion date: Jan 2018 --> Jun 2017
- Bylantra (devimistat) / Cornerstone Pharma, Ono Pharma
Phase classification, Enrollment change, Trial withdrawal: Safety and Effectiveness Study of CPI-613 to Treat Refractory or Relapsed Leukemia and Myelodysplastic Syndrome (clinicaltrials.gov) - Dec 29, 2016
P2a, N=0, Withdrawn, Sponsor: Cornerstone Pharmaceuticals, Inc.
Recruiting --> Active, not recruiting | Trial primary completion date: Jan 2018 --> Jun 2017 Phase classification: P2 --> P2a | N=30 --> 0 | Not yet recruiting --> Withdrawn
- adavosertib (AZD1775) / AstraZeneca, Beleodaq (belinostat) / Aurobindo, Assertio
Enrollment change, Combination therapy: Phase I Trial of AZD1775 and Belinostat in Treating Patients With Relapsed or Refractory Myeloid Malignancies or Untreated Acute Myeloid Leukemia (clinicaltrials.gov) - Dec 29, 2016
P1, N=13, Recruiting, Sponsor: National Cancer Institute (NCI)
Phase classification: P2 --> P2a | N=30 --> 0 | Not yet recruiting --> Withdrawn N=24 --> 13
- mocetinostat (MGCD0103) / Otsuka, BMS
Trial primary completion date, Combination therapy: Safety Study of Mocetinostat in Combination With Azacitidine in Subjects With MDS (clinicaltrials.gov) - Dec 27, 2016
P1/2, N=18, Completed, Sponsor: Mirati Therapeutics Inc.
N=24 --> 13 Trial primary completion date: Dec 2015 --> Sep 2015
- Trial primary completion date: Tissue Banking Study - Polycythemia Vera or Essential Thrombocythemia (PV & ET) Patients (clinicaltrials.gov) - Dec 23, 2016
P=N/A, N=400, Recruiting, Sponsor: Icahn School of Medicine at Mount Sinai
Trial primary completion date: Dec 2015 --> Sep 2015 Trial primary completion date: Jan 2017 --> Dec 2018
- Besremi (ropeginterferon alfa-2b) / PharmaEssentia, AOP Orphan Pharma
Trial primary completion date: PEGINVERA: Safety Study of Pegylated Interferon Alpha 2b to Treat Polycythemia Vera (clinicaltrials.gov) - Dec 23, 2016
P1/2, N=24, Active, not recruiting, Sponsor: AOP Orphan Pharmaceuticals AG
Trial primary completion date: Jan 2017 --> Dec 2018 Trial primary completion date: Dec 2016 --> Dec 2017
- | imatinib / Generic mfg.
Enrollment change: A Study of Gleevec in Patients With Idiopathic Myelofibrosis or Chronic Myelomonocytic Leukemia (CMML) (clinicaltrials.gov) - Dec 23, 2016
P2, N=34, Completed, Sponsor: Dana-Farber Cancer Institute
Trial primary completion date: Dec 2016 --> Dec 2017 N=60 --> 34
- decitabine / Generic mfg.
Trial primary completion date: Genomic Predictors of Decitabine Response in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndromes (clinicaltrials.gov) - Dec 22, 2016
P2, N=125, Recruiting, Sponsor: Washington University School of Medicine
N=60 --> 34 Trial primary completion date: Apr 2018 --> May 2017
- arsenic trioxide / Generic mfg.
Enrollment closed, Enrollment change: Arsenic Trioxide and Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia (CML) (clinicaltrials.gov) - Dec 22, 2016
P1, N=7, Active, not recruiting, Sponsor: Beth Israel Deaconess Medical Center
Trial primary completion date: Apr 2018 --> May 2017 Recruiting --> Active, not recruiting | N=18 --> 7
- volasertib (NBL-001) / Oncoheroes, Notable Labs
Trial termination, Trial primary completion date, Combination therapy, Monotherapy: Trial of Volasertib With or Without Azacitidine in Patients With Myelodysplastic Syndromes (clinicaltrials.gov) - Dec 21, 2016
P1, N=70, Terminated, Sponsor: Boehringer Ingelheim
Recruiting --> Active, not recruiting | N=18 --> 7 Recruiting --> Terminated | Trial primary completion date: Mar 2018 --> Nov 2016
- Synribo (omacetaxine mepesuccinate) / Teva
Enrollment change, Trial withdrawal: A Clinical Trial of Omacetaxine, Azacitidine, and Growth-Colony Stimulating Factor (G-CSF) for Myelodysplastic Syndromes (MDS) (clinicaltrials.gov) - Dec 15, 2016
P1/2, N=0, Withdrawn, Sponsor: University of Florida
Recruiting --> Terminated | Trial primary completion date: Mar 2018 --> Nov 2016 N=50 --> 0 | Not yet recruiting --> Withdrawn
- | Promacta (eltrombopag) / Novartis
Trial completion, Trial primary completion date: Efficacy and Safety of Eltrombopag In Patients With Severe and Very Severe Aplastic Anemia (clinicaltrials.gov) - Dec 14, 2016
P2, N=13, Completed, Sponsor: University of Utah
N=50 --> 0 | Not yet recruiting --> Withdrawn Active, not recruiting --> Completed | Trial primary completion date: Nov 2016 --> Jul 2016
- | Campath (alemtuzumab) / Sanofi
Trial completion: Alemtuzumab and Combination Chemotherapy Followed By Donor Lymphocytes in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer (clinicaltrials.gov) - Dec 14, 2016
P1, N=20, Completed, Sponsor: Yale University
Active, not recruiting --> Completed | Trial primary completion date: Nov 2016 --> Jul 2016 No longer recruiting --> Completed
- talacotuzumab (JNJ-56022473) / J&J
New P2 trial: SAMBA: Single Agent JNJ-56022473 in MDS and AML Patients FAILING HYPOMETHYLATING AGENT BASED THERAPY (clinicaltrials.gov) - Dec 14, 2016
P2, N=43, Recruiting, Sponsor: GWT-TUD GmbH
- Enrollment closed, Enrollment change, Trial primary completion date: Total Marrow Irradiation for Refractory Acute Leukemia (clinicaltrials.gov) - Dec 8, 2016
P1, N=12, Active, not recruiting, Sponsor: Masonic Cancer Center, University of Minnesota
No longer recruiting --> Completed Recruiting --> Active, not recruiting | N=20 --> 12 | Trial primary completion date: Sep 2017 --> Feb 2016
- mycophenolate mofetil / Generic mfg., sirolimus / Generic mfg.
Enrollment closed, Enrollment change, Trial primary completion date: Inducible Regulatory T Cells (iTregs) in Non-Myeloablative Sibling Donor Peripheral Blood Stem Cell Transplantation (clinicaltrials.gov) - Dec 8, 2016
P1, N=16, Active, not recruiting, Sponsor: Masonic Cancer Center, University of Minnesota
Recruiting --> Active, not recruiting | N=20 --> 12 | Trial primary completion date: Sep 2017 --> Feb 2016 Recruiting --> Active, not recruiting | N=22 --> 16 | Trial primary completion date: Dec 2016 --> Sep 2016
- Synribo (omacetaxine mepesuccinate) / Teva
Enrollment closed, Enrollment change: Omacetaxine and Decitabine in Acute Myelogenous Leukemia (AML) and Myelodysplastic Syndrome (MDS) (clinicaltrials.gov) - Dec 7, 2016
P2, N=2, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Recruiting --> Active, not recruiting | N=22 --> 16 | Trial primary completion date: Dec 2016 --> Sep 2016 Recruiting --> Active, not recruiting | N=66 --> 2
- volasertib (NBL-001) / Oncoheroes, Notable Labs
Enrollment change, Trial termination, Trial primary completion date: Trial of Intensive Chemotherapy With or Without Volasertib in Patients With Newly Diagnosed High-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) (clinicaltrials.gov) - Dec 5, 2016
P2, N=6, Terminated, Sponsor: University of Ulm
Recruiting --> Active, not recruiting | N=66 --> 2 N=264 --> 6 | Recruiting --> Terminated | Trial primary completion date: Aug 2017 --> Nov 2016; development program of study drug volasertib was stopped by Boehringer Ingelheim due to manufacturing problems
- cytarabine / Generic mfg., decitabine / Generic mfg.
Enrollment change, Metastases: Decitabine and Cytarabine in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia, High Risk Myelodysplastic Syndrome, or Myeloproliferative Neoplasm (clinicaltrials.gov) - Dec 5, 2016
P=N/A, N=30, Active, not recruiting, Sponsor: University of Washington
N=264 --> 6 | Recruiting --> Terminated | Trial primary completion date: Aug 2017 --> Nov 2016; development program of study drug volasertib was stopped by Boehringer Ingelheim due to manufacturing problems N=12 --> 30
- | Enrollment closed, Enrollment change: Busulfan, Cyclophosphamide, and Melphalan or Busulfan and Fludarabine Phosphate Before Donor Hematopoietic Cell Transplant in Treating Younger Patients With Juvenile Myelomonocytic Leukemia (clinicaltrials.gov) - Nov 30, 2016
P2, N=30, Active, not recruiting, Sponsor: Children's Oncology Group
N=12 --> 30 Suspended --> Active, not recruiting | N=145 --> 30
- decitabine / Generic mfg.
Enrollment closed, Enrollment change: Phase I, Dose Escalation Study of Decitabine (clinicaltrials.gov) - Nov 30, 2016
P1, N=3, Active, not recruiting, Sponsor: University of Florida
Suspended --> Active, not recruiting | N=145 --> 30 Recruiting --> Active, not recruiting | N=36 --> 3
- imatinib / Generic mfg.
New trial: Study of Cemivil (clinicaltrials.gov) - Nov 30, 2016
P=N/A, N=91, Completed, Sponsor: Hikma Pharmaceuticals LLC
- Trial primary completion date: MICROFANC: Microcephaly Genetic Deficiency in Neural Progenitors (clinicaltrials.gov) - Nov 29, 2016
P=N/A, N=135, Recruiting, Sponsor: Assistance Publique - H
Recruiting --> Active, not recruiting | N=36 --> 3 Trial primary completion date: Oct 2016 --> Jun 2017
- Campath (alemtuzumab) / Sanofi
Trial primary completion date: A Pilot Study of Alemtuzumab (Campath[R]) in Patients With Myelodysplastic Syndrome (clinicaltrials.gov) - Nov 23, 2016
P2, N=40, Active, not recruiting, Sponsor: National Heart, Lung, and Blood Institute (NHLBI)
Trial primary completion date: Oct 2016 --> Jun 2017 Trial primary completion date: Dec 2016 --> Mar 2017
- Enrollment closed, Trial primary completion date: Donor Peripheral Stem Cell Transplant in Treating Patients With Hematolymphoid Malignancies (clinicaltrials.gov) - Nov 18, 2016
P1, N=16, Active, not recruiting, Sponsor: Robert Lowsky
Trial primary completion date: Dec 2016 --> Mar 2017 Recruiting --> Active, not recruiting | Trial primary completion date: Mar 2016 --> Sep 2016
- Enrollment change: Fertility Preservation in Women Who Will Have Gonadotoxic Therapy or Hematopoetic Stem Cell Transplantation, and in Women With Sickle Cell Disease (clinicaltrials.gov) - Nov 16, 2016
P=N/A, N=22, Completed, Sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Recruiting --> Active, not recruiting | Trial primary completion date: Mar 2016 --> Sep 2016 N=10 --> 22
- danazol oral / Generic mfg.
Trial completion, Trial primary completion date: Danazol for Genetic Bone Marrow and Lung Disorders (clinicaltrials.gov) - Nov 16, 2016
P1/2, N=27, Completed, Sponsor: National Heart, Lung, and Blood Institute (NHLBI)
N=10 --> 22 Active, not recruiting --> Completed | Trial primary completion date: Mar 2017 --> Nov 2016
- | Trial completion: Dexamethasone for Pain Flare After Radiotherapy of Painful Bone metastasesZonMW 11510009 (clinicaltrials.gov) - Nov 16, 2016
P3, N=411, Completed, Sponsor: UMC Utrecht
Active, not recruiting --> Completed | Trial primary completion date: Mar 2017 --> Nov 2016 Recruiting --> Completed
- daunorubicin / Generic mfg., cyclophosphamide / Generic mfg., decitabine / Generic mfg.
Trial completion: Study of Molecular and Genetic Abnormalities in Patients With Myeloid Neoplasms (clinicaltrials.gov) - Nov 8, 2016
P2, N=455, Completed, Sponsor: Hospital Israelita Albert Einstein
Recruiting --> Completed Active, not recruiting --> Completed
- |||| lenalidomide / Generic mfg.
Trial completion, Trial primary completion date: Lenalidomide in Subject With Low and Intermediate-1 Risk MDS and Without Chromosome 5 Abnormality. (clinicaltrials.gov) - Nov 8, 2016
P2, N=132, Completed, Sponsor: Groupe Francophone des Myelodysplasies
Active, not recruiting --> Completed Active, not recruiting --> Completed | Trial primary completion date: Jun 2015 --> Nov 2012
- Enrollment open, Trial primary completion date: MPN: Registry of Philadelphia-Negative Myeloproliferative Neoplasms (clinicaltrials.gov) - Nov 8, 2016
P=N/A, N=500, Recruiting, Sponsor: Hospital Israelita Albert Einstein
Active, not recruiting --> Completed | Trial primary completion date: Jun 2015 --> Nov 2012 Not yet recruiting --> Recruiting | Trial primary completion date: Mar 2015 --> Dec 2018
- Trial initiation date: StemRegenin-1 Expanded vs Unexpanded UCB for High Risk Heme Malignancies (clinicaltrials.gov) - Nov 8, 2016
P2, N=30, Not yet recruiting, Sponsor: Masonic Cancer Center, University of Minnesota
Not yet recruiting --> Recruiting | Trial primary completion date: Mar 2015 --> Dec 2018 Initiation date: Jun 2016 --> Jan 2017
- melphalan / Generic mfg., fludarabine IV / Generic mfg., thiotepa / Generic mfg.
Enrollment closed, Enrollment change: Biparental HLA Haplotype Disparate T-cell Depleted Transplants for Patients Lacking an HLACompatible Donor (clinicaltrials.gov) - Nov 1, 2016
P=N/A, N=3, Active, not recruiting, Sponsor: Memorial Sloan Kettering Cancer Center
Initiation date: Jun 2016 --> Jan 2017 Recruiting --> Active, not recruiting | N=21 --> 3
- volasertib (NBL-001) / Oncoheroes, Notable Labs
Trial primary completion date, Combination therapy: Phase I Dose Escalation Trial of Volasertib in Combination With Azacitidine in Patients With MDS or CMML (clinicaltrials.gov) - Oct 31, 2016
P1, N=88, Suspended, Sponsor: Boehringer Ingelheim
Recruiting --> Active, not recruiting | N=21 --> 3 Trial primary completion date: Jun 2017 --> Jun 2018
- volasertib (NBL-001) / Oncoheroes, Notable Labs
Trial initiation date, Trial primary completion date: VIAC: A Study of Volasertib Plus Induction Chemotherapy for Acute Myeloid Leukemia (clinicaltrials.gov) - Oct 28, 2016
P1, N=30, Not yet recruiting, Sponsor: University of Alberta
Trial primary completion date: Jun 2017 --> Jun 2018 Initiation date: Jun 2016 --> Nov 2016 | Trial primary completion date: Dec 2017 --> May 2018
- Vyxeos (cytarabine/daunorubicin liposomal formulation) / Jazz, Nippon Shinyaku
Trial primary completion date: Liposomal Cytarabine-Daunorubicin CPX-351 in Treating Patients With Untreated Myelodysplastic Syndrome or Acute Myeloid Leukemia (clinicaltrials.gov) - Oct 26, 2016
P=N/A, N=90, Recruiting, Sponsor: Fred Hutchinson Cancer Research Center
Initiation date: Jun 2016 --> Nov 2016 | Trial primary completion date: Dec 2017 --> May 2018 Trial primary completion date: Dec 2016 --> Jun 2017
- Sylvant (siltuximab) / Jazz
Enrollment change, Trial withdrawal: Siltuximab in Treating Patients With Primary, Post-Polycythemia Vera, or Post-Essential Thrombocythemia Myelofibrosis (clinicaltrials.gov) - Oct 25, 2016
P0, N=0, Withdrawn, Sponsor: Northwestern University
Trial primary completion date: Dec 2016 --> Jun 2017 N=12 --> 0 | Not yet recruiting --> Withdrawn
- Thymoglobulin (anti-thymocyte globulin (rabbit)) / Sanofi
Enrollment open, Trial initiation date, Trial primary completion date: Tacrolimus, Bortezomib, & Thymoglobulin in Preventing Low Toxicity GVHD in Donor Blood Stem Cell Transplant Patients (clinicaltrials.gov) - Oct 25, 2016
P2, N=38, Recruiting, Sponsor: Emory University
N=12 --> 0 | Not yet recruiting --> Withdrawn Not yet recruiting --> Recruiting | Initiation date: Feb 2017 --> Sep 2016 | Trial primary completion date: Feb 2019 --> Sep 2018
- Tasigna (nilotinib) / Novartis, Inhibikase
Enrollment open, Trial initiation date, Trial primary completion date: Dasatinib or Nilotinib Followed by Imatinib in Patients With Newly Diagnosed, Chronic Phase Chronic Myeloid Leukemia (clinicaltrials.gov) - Oct 21, 2016
P2, N=100, Recruiting, Sponsor: Emory University
Not yet recruiting --> Recruiting | Initiation date: Feb 2017 --> Sep 2016 | Trial primary completion date: Feb 2019 --> Sep 2018 Not yet recruiting --> Recruiting | Initiation date: Mar 2017 --> Oct 2016 | Trial primary completion date: Mar 2020 --> Oct 2019
- Trial primary completion date: MR-HIFU for Bone Metastases (clinicaltrials.gov) - Oct 20, 2016
P=N/A, N=12, Active, not recruiting, Sponsor: Institute of Cancer Research, United Kingdom
Not yet recruiting --> Recruiting | Initiation date: Mar 2017 --> Oct 2016 | Trial primary completion date: Mar 2020 --> Oct 2019 Trial primary completion date: Sep 2016 --> Dec 2016
- cytarabine / Generic mfg., clofarabine / Generic mfg.
Trial primary completion date: Clofarabine Plus Low-Dose Cytarabine for Patients With Higher-Risk Myelodysplastic Syndrome (MDS) (clinicaltrials.gov) - Oct 19, 2016
P2, N=80, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Trial primary completion date: Sep 2016 --> Dec 2016 Trial primary completion date: Apr 2017 --> Apr 2018